Compare MESO & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MESO | JBLU |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | Australia | United States |
| Employees | 108 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2005 | 2002 |
| Metric | MESO | JBLU |
|---|---|---|
| Price | $14.52 | $4.25 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $4.91 |
| AVG Volume (30 Days) | 157.0K | ★ 16.6M |
| Earning Date | 02-26-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,062,000,000.00 |
| Revenue This Year | $629.74 | $12.11 |
| Revenue Next Year | $30.65 | $6.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.05 | $3.87 |
| 52 Week High | $21.50 | $6.62 |
| Indicator | MESO | JBLU |
|---|---|---|
| Relative Strength Index (RSI) | 39.88 | 36.58 |
| Support Level | $14.18 | $3.87 |
| Resistance Level | $16.06 | $5.27 |
| Average True Range (ATR) | 0.42 | 0.16 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 13.93 | 9.09 |
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.